Stelara™ (ustekinumab) – New indication
September 26, 2016 – Janssen announced the FDA approval of Stelara (ustekinumab) for the treatment of adult patients with moderately to severely active Crohn’s disease (CD) who have failed or were intolerant to treatment with immunomodulators or corticosteroids, but never failed treatment with a tumor necrosis factor (TNF) blocker; or failed or were intolerant to treatment with one or more TNF blockers.
Top